Literature DB >> 5771197

Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a sponteneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis.

F L Lieberman, S Ito, T B Reynolds.   

Abstract

A reduction in effective (nonportal) plasma volume is considered the basis for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), and a fall in GFR occurring during drug-induced diuresis in patients with cirrhosis and ascites. In the present study the concept of a reduced effective plasma volume in cirrhosis is challenged by two lines of evidence, even though effective plasma volume itself could not be measured. (a) Total plasma volume failed to rise in 10 patients with the spontaneous loss of ascites, the appearance of sodium in the urine, and a rise in GFR. Portal pressure remained constant in these patients as ascites left, suggesting that effective plasma volume had not increased while portal plasma volume decreased. (b) Reduction of GFR could not be prevented in five patients with cirrhosis and ascites while total plasma volume was prevented from falling with albumin infusions during drug-induced diuresis. Reduction of GFR during drug-induced diuresis in 15 patients with cirrhosis and ascites was completely reversed with saline infusion despite continued diuresis with the identical drugs, excluding drug nephrotoxicity as the cause for the reduced GFR. The ascites of cirrhosis might no longer be regarded as a cause of effective plasma volume contraction, stimulating renal sodium retention and a reduction in GFR. More likely, this form of ascites is a result of plasma volume expansion and sodium retention. The causes for renal sodium retention and a spontaneous reduction in GFR remain unknown. The cause for a fall in GFR during drug-induced diuresis also remains unknown, but effective plasma volume contraction and drug nephrotoxicity seem excluded.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5771197      PMCID: PMC322311          DOI: 10.1172/JCI106078

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Modified reagents for determination of urea and ammonia.

Authors:  A L CHANEY; E P MARBACH
Journal:  Clin Chem       Date:  1962-04       Impact factor: 8.327

2.  The bearing of portal vein congestion on the state of the circulation in cirrhosis of the liver.

Authors:  J OFSTAD
Journal:  Acta Med Scand       Date:  1960-10-17

3.  The role of the kidney in Laennec's cirrhosis of the liver.

Authors:  S PAPPER
Journal:  Medicine (Baltimore)       Date:  1958-12       Impact factor: 1.889

4.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

5.  Blood volume in patients with Laennec's cirrhosis of the liver as determined by radioactive chromium-tagged red cells.

Authors:  S EISENBERG
Journal:  Am J Med       Date:  1956-02       Impact factor: 4.965

6.  The use of ethacrynic acid in patients with cirrhosis and ascites.

Authors:  F L Lieberman; T B Reynolds
Journal:  Gastroenterology       Date:  1965-11       Impact factor: 22.682

7.  Portal blood flow in cirrhosis of the liver.

Authors:  A H Moreno; A R Burchell; L M Rousselot; W F Panke; F Slafsky; J H Burke
Journal:  J Clin Invest       Date:  1967-03       Impact factor: 14.808

8.  Hemodynamics in the cirrhotic patient during paracentesis.

Authors:  C M Knauer; H M Lowe
Journal:  N Engl J Med       Date:  1967-03-02       Impact factor: 91.245

9.  Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure.

Authors:  F L Lieberman; T B Reynolds
Journal:  J Clin Invest       Date:  1967-08       Impact factor: 14.808

10.  Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion.

Authors:  F E Tristani; J N Cohn
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

View more
  17 in total

Review 1.  The endocrinology and pathophysiology of alcoholic cirrhosis and functional renal failure--a review.

Authors:  E S Domurat; A N Elias
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

2.  A rational approach to the treatment of ascites.

Authors:  V Arroyo; J Rodés
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

3.  Natriuretic hormone--its possible role in fluid and electrolyte disturbances in chronic liver disease.

Authors:  H J Kramer
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

4.  Role of vagal neuropathy in the hyponatraemia of alcoholic cirrhosis.

Authors:  G Decaux; P Cauchie; A Soupart; M Kruger; F Delwiche
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-13

5.  A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.

Authors:  Kiwamu Okita; Isao Sakaida; Mitsuru Okada; Akira Kaneko; Kazuaki Chayama; Michio Kato; Michio Sata; Harumasa Yoshihara; Naomasa Yoshihara; Noriyuki Ono; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2010-04-13       Impact factor: 7.527

Review 6.  Renal changes in cirrhosis.

Authors:  M Kew
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

Review 7.  Ascites and oedema in liver disease.

Authors:  M S Losowsky; B B Scott
Journal:  Br Med J       Date:  1973-08-11

8.  Recovery from "hepatorenal syndrome" after orthotopic liver transplantation.

Authors:  S Iwatsuki; M M Popovtzer; J L Corman; M Ishikawa; C W Putnam; F H Katz; T E Starzl
Journal:  N Engl J Med       Date:  1973-11-29       Impact factor: 91.245

9.  Use of amiloride as a potassium conserving agent in severe cardiac disease.

Authors:  C Davidson; I M Gillebrand
Journal:  Br Heart J       Date:  1973-04

10.  [Hepato-renal syndrome (author's transl)].

Authors:  J Kipnowski; R Düsing; H J Kramer
Journal:  Klin Wochenschr       Date:  1981-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.